Prior to joining Barrier, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson from 1982 to 2003. He completed his tenure with Johnson & Johnson as General Manager of Ortho Neutrogena, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. Mr. Altomari also served as Vice President/Franchise Head of Ortho-McNeil Pharmaceutical's Women's Health Care Franchise, where he introduced several life cycle and new product development initiatives, including the launch of the contraceptive patch, ORTHO Evra ™.Mr. Altomari currently serves as a member of the Boards of Directors of DUSA Pharmaceuticals and Nitric Bio Therapeutics. In July 2007, he was recognized by PharmaVoice Magazine as one of the Top 100 Most Inspirational and Influential leaders in the Life Sciences Industry. He received a Masters in Business Administration from Rider University and his Bachelor of Science from Drexel University. Mr. Altomari also serves on the advisory board for Le Bow College, Drexel University's business school. "With top-line data for ARIKACE in the Company's lead orphan indications, cystic fibrosis-related Pseudomonas lung infections and non-TB Mycobacteria lung infections, expected in 2013, this is an exciting time to be joining Insmed's Board," said Mr. Altomari. "I look forward to lending my specialty pharmaceutical development and marketing expertise to the Company's Board and management team." About Insmed Insmed Incorporated is a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, with a particular focus on orphan diseases. Insmed's core expertise is the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology. For more information, please visit http://www.insmed.com.